Dr. Cheng joined Morningside in 2006 and focuses on biopharmaceutical and healthcare investments. He is currently a director of Liquidia Technologies, Cognoa, K-Gen, Artugen Therapeutics, Cognito Therapeutics, Amylyx Pharmaceuticals, and NuCana BioMed. Previously he was a board member of Advanced Cell Diagnostics (sold to Bio-Techne). Prior to joining Morningside, Dr. Cheng was Director of Research and Development at Serica Technologies, a Morningside portfolio company that was sold to Allergan. In addition, Dr. Cheng was previously an Associate Director at Novartis Pharmaceuticals in Clinical Development and Medical Affairs. Dr. Cheng received his M.D. from Tufts University School of Medicine. He is the recipient of numerous honors and awards including the Howard Hughes Medical Institute Research Fellowship, which supported his research under Dr. Rudy Tanzi at Massachusetts General Hospital / Harvard Medical School.Visit Isaac’s LinkedIn profile to learn more
Mr. Von Coerper began serving as a director of Amylyx in 2016. Mr. Von Coerper currently is the managing partner of the ALS Investment Fund, a venture capital fund based in the Netherlands exclusively focused on investment in promising ALS technologies. He has over 19 years experience in early stage venture management & finance. He founded a served as CEO of Elana and was CEO of MySample BV. He received his Masters in Economics from the Erasmus University Rotterdam.Visit Felix’s LinkedIn profile to learn more
Josh Cohen co-founded Amylyx Pharmaceuticals in 2013 and has served since that time as its Co-CEO, its Co-Founder, and as Chairman of the board of directors. Josh co-invented AMX0035 and has overseen the growth of Amylyx from its start as a concept dreamed up in a dorm room to its status now as a pre-commercial stage pharmaceutical company. Together with Justin, Josh has raised nearly $250M in financing to support the development of new therapies for ALS and other neurodegenerative diseases. Josh received his Bachelor of Science in Biomedical Engineering from Brown University.Visit Josh’s LinkedIn profile to learn more
Paul Fonteyne began serving as a director of Amylyx in 2021. Mr. Fonteyne has more than thirty years of experience in the pharmaceutical industry, including in leadership positions focused on the commercialization of innovative treatments for patients around the globe. Most notably, he was with Boehringer Ingelheim for over 15 years where he served as the U.S. President and CEO for seven years, then subsequently Chairman until his retirement in January in 2019. During his tenure at Boehringer Ingelheim, Mr. Fonteyne helped drive the company’s annual top line sales in the USA significantly upwards and oversaw the successful U.S. launch of the company’s top selling products. Prior, he held commercial leadership roles at Merck and Co. Inc. from 1994-2003 and Abbott Laboratories from 1987-1995. He has served on the board of PhRMA, chaired the National Pharmaceutical Council and served as Chair of an American Cancer Society initiative for New England known as CEOs against Cancer. Mr. Fonteyne received an M.S. in Chemical Engineering from the University of Brussels and an MBA from Carnegie Mellon University.Visit Paul’s LinkedIn profile to learn more
Justin Klee co-founded Amylyx Pharmaceuticals in 2013 and continues to serve as its Co-CEO and Co-Founder. Justin has overseen the development of Amylyx’s novel platform and therapeutic for neurodegenerative diseases from initial testing through clinical trials. Justin previously did research in neural systems while at Brown University and in neurophysiology and Alzheimer’s disease at Harvard Medical School. He received his Bachelor of Science in Neuroscience from Brown University.Visit Justin’s LinkedIn profile to learn more
Dr. Milne began serving as a director of Amylyx in 2015. From 1993 to 2000, Dr. Milne served as President of Central Research for Pfizer, Inc. and oversaw both human and veterinary research and development. George M. Milne, Jr., Ph.D. became a Radius Venture Partner in 2002. Milne has served on the Board of Directors at many different companies and organizations including currently Charles River Laboratories, Mettler-Toledo, Inc., BioStorage Technologies Inc., Draper Laboratory, the Sea Research Foundation, and the New York Botanical Garden. During his notable career, Milne has received a variety of honors, including an award from Yale University for lifetime contributions to commerce, innovation or education, the Connecticut College medal, and the distinguished citizen award from Big Brothers/Big Sisters. Dr. Milne received a B.S. in Chemistry from Yale University and a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology.Visit George’s LinkedIn profile to learn more
Daphne Quimi began serving as a director of Amylyx in 2021. Ms. Quimi has more than 25 years of executive experience in the pharmaceutical and biotechnology industries with expertise in global finance operations, company building, and rare disease drug commercialization. She currently serves as Chief Financial Officer (CFO) of Amicus Therapeutics. Ms. Quimi joined Amicus when it was a pre-commercial company and has the experience of helping build Amicus through its first regulatory approvals and launches for Galafold™ in the U.S., Europe, Canada and Japan. As CFO at Amicus, Ms. Quimi is responsible for directing all financial activities, including strategic planning, financial reporting and budgeting, investor relations and shareholder engagement. Prior to her roles at Amicus, Ms. Quimi served as Director of Consolidations and External Reporting at Bristol-Myers Squibb and held roles of increasing responsibility in the finance division at Johnson & Johnson. She has also served as an auditor at KPMG. Ms. Quimi received a B.S. in Accountancy from Monmouth University in New Jersey and an MBA from the Stern School of Business of New York University.Visit Daphne’s LinkedIn profile to learn more
Walter (Wally) Gilbert is a renowned scientist who was awarded the 1980 Nobel Prize in Chemistry for his discovery of a method for rapid DNA sequencing. His forty-year academic career at Harvard University was marked by many discoveries, including messenger RNA, genetic repressors, DNA sequencing, and the first expression of insulin in bacteria.
Dr. Gilbert is the Carl M. Loeb University Professor Emeritus at Harvard University. He is currently a managing director at BioVentures Investors, a venture capital fund in Cambridge, MA. In 1978 Dr. Gilbert co-founded Biogen, the world’s oldest independent biotechnology company. He served as Chair of the Scientific Board of Directors from 1978 to 1983, Co-Chairman of the Supervisory Board of Directors from 1979 to 1981, Chairman of the Supervisory Board of Directors from 1981 to 1985, and Chief Executive Officer from 1981 to 1985. As CEO, Dr. Gilbert oversaw the company’s Initial Public Offering in 1983 and played a key role in the development of several key products, including alpha interferon, beta interferon, and hepatitis B vaccine. In 1992, Dr. Gilbert co-founded Myriad Genetics and continues to serve as its Vice-Chairman. In 1996, Dr. Gilbert co-founded Paratek Pharmaceuticals and served as its Chairman until 2014.Visit Wally’s LinkedIn profile to learn more
Dr. Walts is a Board Observer and Advisor to Amylyx. Alan has broad experience in the Life Science industry and serves as Executive Chairman of Aura Biosciences, Executive Chairman of Artax Biopharma, as a Director of X4 Pharmaceuticals and as a Director of Arrakis Therapeutics. Alan was a Business Advisor to the late Henri Termeer, and worked closely with Henri on founding and investing in early-stage companies. Alan is also a US-based Venture Partner with Advent Life Sciences. Alan has over 25 years of industry experience in venture capital, business development, research and development, and general management at Genzyme Corporation. Prior to leaving Genzyme in 2013, Alan managed Genzyme’s corporate venture fund, Genzyme Ventures (now Sanofi-Genzyme BioVentures). Alan received a Ph.D. in chemistry from MIT in 1985, carried out post-doctoral research in biochemistry at MIT with Professor Christopher Walsh, and completed the Executive Program for Management Development at Harvard Business School.Visit Alan’s LinkedIn profile to learn more
Mr. Termeer began serving as a board observer at Amylyx in 2016. He passed away on May 12th, 2017. Henri was an advocate for patients and an incredible mentor to the company. He was instrumental in helping Amylyx become a clinical-stage company and always impressed upon us the need to keep patients at the center of decisions. He will be sorely missed but we are thankful for the time we were able to spend with him.Visit Henri’s LinkedIn profile to learn more
For inquiries or further information, please do not hesitate to contact us.